


DHMEQ racemate

Cat. No.:	HY-14645B
CAS No.:	287194-38-1
Molecular Formula:	C ₁₃ H ₁₁ NO ₅
Molecular Weight:	522.47
Target:	NF-κB
Pathway:	NF-κB
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 32 mg/mL (61.25 mM)
 * "≥" means soluble, but saturation unknown.

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	1.9140 mL	9.5699 mL	19.1399 mL
	5 mM	0.3828 mL	1.9140 mL	3.8280 mL
	10 mM	0.1914 mL	0.9570 mL	1.9140 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description	DHMEQ racemate is a NF-κB inhibitor. DHMEQ racemate is less active than (-)-DHMEQ.
IC₅₀ & Target	NF-κB
In Vitro	DHMEQ racemate (DHM3EQ) and (-)-DHMEQ (DHM2EQ) inhibits TNF-α-induced NF-κB activation. (-)-DHMEQ is more potent and less toxic than DHMEQ racemate ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	The antiarthritic effects of (-)-DHMEQ (DHM2EQ) and DHMEQ racemate (DHM3EQ) are examined on type-II collagen-induced arthritis in DBA1/J mice. This animal model is widely used for evaluation of antirheumatic drugs because of its pathological similarities to human rheumatoid arthritis. The arthritis is elicited and scored. (-)-DHMEQ markedly inhibits type-II-collagen-induced arthritis in mice, whereas DHMEQ racemate tends to only slightly inhibit it ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Matsumoto N, et al. Synthesis of NF-kappaB activation inhibitors derived from epoxyquinomicin C. Bioorg Med Chem Lett. 2000 May 1;10(9):865-9.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA